Patents by Inventor Laura Ann Marlow
Laura Ann Marlow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230201192Abstract: This document relates to methods and materials involved in assessing and/or treating mammals (e.g., humans) having cancer (e.g., a SCD1-associated cancer). For example, methods for determining whether or not a cancer is likely to be responsive to one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors (e.g., a selective SCD1 inhibitor (SSI)) are provided. In some cases, the methods and materials for treating a mammal by administering, to the mammal, one or more cancer treatments that is/are selected based, at least in part, on whether or not the mammal is likely to be responsive to one or more SCD1 polypeptide inhibitors e.g., SSI-4) are provided.Type: ApplicationFiled: June 16, 2021Publication date: June 29, 2023Inventors: John A. Copland, III, Laura Ann Marlow
-
Publication number: 20220411389Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: April 5, 2022Publication date: December 29, 2022Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 11325892Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: GrantFiled: May 24, 2019Date of Patent: May 10, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 11243207Abstract: This document relates to methods and materials for identifying and/or treating mammals having cancer (e.g., a SCD1-associated cancer). For example, methods and materials for using one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors to treat a mammal having cancer (e.g., a SCD1-associated cancer) are provided.Type: GrantFiled: March 28, 2019Date of Patent: February 8, 2022Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow
-
Publication number: 20190345123Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: May 24, 2019Publication date: November 14, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20190302121Abstract: This document relates to methods and materials for identifying and/or treating mammals having cancer (e.g., a SCD1-associated cancer). For example, methods and materials for using one or more stearoyl CoA desaturase 1 (SCD1) polypeptide inhibitors to treat a mammal having cancer (e.g., a SCD1-associated cancer) are provided.Type: ApplicationFiled: March 28, 2019Publication date: October 3, 2019Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow
-
Patent number: 10301273Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: GrantFiled: August 7, 2015Date of Patent: May 28, 2019Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Patent number: 10160972Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: GrantFiled: August 31, 2017Date of Patent: December 25, 2018Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Publication number: 20170362595Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: ApplicationFiled: August 31, 2017Publication date: December 21, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Publication number: 20170226073Abstract: This document provides compounds, compositions, and methods for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, compounds, compositions, and methods for using one or more inhibitors of SCD1 to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)), thyroid cancer, or liver cancer; or to increase the efficacy of treatment for the same.Type: ApplicationFiled: August 7, 2015Publication date: August 10, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Han W. Tun, Thomas R. Caulfield, Christina Von Roemeling, Laura Ann Marlow
-
Publication number: 20160152986Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: ApplicationFiled: December 7, 2015Publication date: June 2, 2016Inventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Patent number: 9233102Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: GrantFiled: March 7, 2013Date of Patent: January 12, 2016Assignee: Mayo Foundation for Medical Education and ResearchInventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Publication number: 20150045418Abstract: This document provides methods and materials for treating cancers including renal cancer (e.g., renal cell carcinoma) as well as ovarian, breast, prostate, colon, pancreatic, bladder, liver, lung, and thyroid cancers and melanoma. For example, methods and material for using one or more inhibitors of an SCD1 polypeptide to treat renal cell carcinoma (e.g., clear cell renal cell carcinoma (ccRCC)) or to increase the efficacy of a renal cell carcinoma treatment are provided. In addition, this document provides methods and materials for using elevated SCD1 expression levels in diseased tissues as an indication that an SCD1 inhibitor can be used as an appropriate therapeutic to ameliorate the disease.Type: ApplicationFiled: March 7, 2013Publication date: February 12, 2015Inventors: John A. Copland, III, Laura Ann Marlow, Christina Von Roemeling
-
Publication number: 20130244950Abstract: Methods of treating, preventing or managing triple negative breast cancer (TNBC) or clear cell renal cell carcinoma (ccRCC) are disclosed. The methods encompass the administration of an HDAC inhibitor romidepsin in combination with a cytidine analog. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.Type: ApplicationFiled: September 26, 2012Publication date: September 19, 2013Applicant: Celgene CorporationInventors: John A. Copland, III, Han Win Tun, Simon James Cooper, Laura Ann Marlow